Biohaven Pharma (BHVN) Misses Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/9/2026
- S&P 500, Nasdaq rise as tech, chipmakers rebound
- Oil prices settle $1 higher after Iran and Israel say they have halted attacks
- Tech stocks gain as Trump mulls government stake in AI companies
- Morgan Stanley’s Wilson calls Friday U.S. selloff a "healthy reset"
- Hedge funds loaded up on equities ahead of sharp Friday drop
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Exclusive-SpaceX plans to set IPO price at $135 per share, targeting record $75 billion raise, source says
- Salesforce to acquire metering platform M3TER for consumption billing
- SpaceX sets $135 price for blockbuster IPO, upending Wall Street convention
- Quantum Space to go public via $1.2B SPAC merger
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $66 at RBC Capital
November 13, 2024 6:44 AM ESTRBC Capital analyst Leonid Timashev lowered the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $66.00 (from $68.00) while maintaining a Outperform rating.
The analyst comments "This afternoon BHVN reported 3Q24 earnings. The company's pipeline remains on track for key value... More
